The effect of lanthanum carbonate on calciprotein particles in hemodialysis patients

Kimihiko Nakamura1 · Yudai Nagata1,2 · Toshiya Hiroyoshi1 · Naohito Isoyama1 · Koki Fujikawa1 · Yutaka Miura3 · Hideyasu Matsuyama1 · Makoto Kuro-o3

Received: 10 October 2019 / Accepted: 9 December 2019 / Published online: 26 December 2019
© The Author(s) 2019

Abstract

Background Aggregation of solid-phase calcium–phosphate and fetuin-A form nanoparticles called calciprotein particles (CPP). Serum CPP levels are increased in CKD patients and correlated with vascular stiffness and calcification. In this study, we evaluated effects of lanthanum carbonate (LC) and calcium carbonate (CC) on serum CPP levels in hemodialysis (HD) patients.

Methods Twenty-four (24) HD patients (50% men, age; 68 ± 12 years, dialysis period; 6.2 ± 4.8 years, Kt/v; 1.74 ± 0.34) were treated with CC during 0–8 weeks and then switched to LC during 9–16 weeks. Blood samples were obtained at 0, 8, 16 weeks. Serum CPP levels (TCPP) were measured by the gel-filtration method. Low-density CPP (LCPP) levels were determined by centrifuging the serum samples at 16,000 g for 2 h and measuring CPP levels in the supernatant. The difference between TCPP and LCPP was defined as the high-density CPP (HCPP) level. We evaluated association of TCPP, LCPP, and HCPP with serum calcium (Ca), phosphorus (P), intact PTH, FGF23, Klotho, fetuin-A, aortic calcification index (ACI), LDL cholesterol, and hs-CRP.

Results TCPP and LCPP levels were significantly decreased after switching CC to LC, whereas Ca and P levels were not changed. HCPP levels were below the lower limit quantification in all patients. The changes in P, Ca × P, LDL cholesterol, but not ACI and the changes in hs-CRP, were correlated with the change in TCPP levels.

Conclusion The TCPP levels were significantly decreased after switching CC to LC. Non-calcium-containing phosphate binders may be preferable for lowering CPP levels.

Keywords Calciprotein particles · Hemodialysis · Lanthanum carbonate

Introduction

Patients with renal failure suffer from disorders in bone and mineral metabolism, which are collectively called chronic kidney disease–mineral and bone disorder (CKD–MBD). CKD–MBD is associated with cardiovascular and soft tissue calcification [1]. Specifically, hyperphosphatemia has been identified as a major risk factor for cardiovascular mortality and morbidity in CKD patients on dialysis [2].

When concentrations of calcium and phosphate exceed the solubility limit in the blood, calcium–phosphate crystals precipitate, to which mineral-binding proteins in the serum such as fetuin-A bind and inhibit growth of the crystals [3]. As a result, nanoparticles of calcium–phosphate crystals and fetuin-A are generated, which are called calciprotein particles (CPP). Thus, formation of CPP is regarded as a defense mechanism to prevent calcium–phosphate crystals from growing to large precipitates in the blood [4]. However, recent studies have shown that CPP have the ability to induce calcification and cell death in cultured vascular smooth muscle cells and inflammatory responses in cultured macrophages [5–7]. Furthermore, serum CPP levels are increased with CKD progression.
and correlated with vascular stiffness and calcification [8, 9]. Taken together, these findings have raised the possibility that CPP may function as a pathogen of vascular calcification, a major risk for cardiovascular mortality and morbidity.

Phosphate binders have been prescribed for patients with hyperphosphatemia. Calcium carbonate (CC) is one of the most widely used phosphate binders. However, some clinical studies have indicated that CC is associated with severer vascular calcification when compared with non-calcium-based phosphate binders such as lanthanum carbonate (LC), possibly because administration of calcium may cause hypercalcemia and VC [10]. LC is a phosphate binder that does not contain calcium. Some studies revealed that LC suggests a benefit on reducing VC, but the effect of LC on CPP is not known.

In this study, we tested whether the serum CPP levels would be reduced by treatment with CC or LC in HD patients.

**Materials and methods**

**Patients**

This prospective study comprised 24 end-stage renal disease (ESRD) patients undergoing HD [50% men, median age 68 (range 40–84) years]. The selection criteria were: patients with hyperphosphatemia treated with CC, age older than 20 years. The exclusion criteria were: already treated with LC, treated by parathyroidectomy or percutaneous ethanol injection therapy of parathyroid, undergoing peritoneal dialysis, the presence of serious digestive disturbance or liver dysfunction, pregnant or lactating.

Patient’s case history and comorbidities were obtained from medical records. The causes of kidney disease were diabetic nephropathy (46%), chronic glomerular nephritis (21%), hypertensive nephrosclerosis (13%), polycystic kidney disease (4%) and others (16%). They were taking 1,25-dihydroxyvitamin D3 (80%) and calcimimetics (17%).

Comorbidities included hypertension (83%), diabetes mellitus (46%), cardiovascular disease defined as cardiac, cerebrovascular (including stroke) (38%) patients, secondary hyperparathyroidism (33%), and others (25%).

**The dialysis powder was KIDOLIME T-30 (FUSO Pharmaceutical Industries, Ltd., Osaka, Japan). Ca²⁺ of hemodialysis fluid is 3.0 mEq/L.**

**Study design**

This prospective study was conducted from 2012 through 2013 in two community hospitals. Patients with hyperphosphatemia and treated with CC were enrolled and treated continuously with CC during 0–8 weeks, followed by LC during 9–16 weeks (Fig. 1). Considering the fact that the ability of LC to adsorb phosphate is about twofold higher than that of CC [11], the starting dose of LC was half dose of CC or 750 mg/day. During the study period, serum calcium (Ca) and phosphorus (P) concentration were measured every 2 weeks to adjust the dose of CC and LC depending on their concentration. Serum CPP levels were measured at the beginning of the study (the 0th week) and the end of the CC treatment (the 8th week) and the LC treatment (the 16th week) to test for correlation with serum Ca, P, intact PTH, FGF23, Klotho, fetuin-A, aortic calcification index (ACI), LDL cholesterol, and hs-CRP at the same time points.

**Blood sampling and laboratory analysis**

Blood samples were collected from patients before starting HD at the beginning of the week. Fetuin-A (ELISA Kit, Biovendor), FGF-23 (ELISA Kit, Kainos), Klotho (Soluble α-Klotho Assay Kit, IBL) and hs-CRP (N-latex CRP II, SIE- MENS) were measured by FALCO biosystems Ltd. Other laboratory data were analyzed using certified methods at the Department of Clinical Chemistry of each hospital.

**Measurement of aortic calcification index (ACI)**

We evaluated ACI using multislice computed tomography (16-slice configuration, SOMATOM Emotion, SIEMENS, Tokyo,
Japan) and expressed calcification in 12 sectors as a percentage (%). Slices of the abdominal aorta area were obtained from diaphragm to bifurcation of the common iliac artery. Mean value was calculated for the number of obtained slices [12].

**Measurement of CPP by the gel-filtration method**

Serum CPP levels were measured as we reported previously with minor modifications [13]. Briefly, 5 μl of heparin plasma was added to 45 μl of Dulbecco’s Modified Eagle Medium (DMEM) containing 100 mM HEPES (pH 8.0) supplemented with 0.5 μM OsteoSense 680EX (PerkinElmer). After incubation at 25 °C for 60 min, 30 μl of the mixture was applied to a gel-filtration spin column (Bio-rad, molecular weight cutoff 40 kDa) and centrifuged at 1000 g for 2 min. 50 μl of the flow-through was diluted with the same volume of 2% SDS and 100 mM EDTA to avoid quenching, and subjected to the quantification of fluorescence using an infrared fluorescence scanner (Odyssey CLx, LI-COR, excitation at 685 nm, emission at 700 nm). The fluorescence intensity of OsteoSense was defined as the total CPP level (TCPP). The same assay was repeated using the supernatant after the plasma was centrifuged at 16,000 g for 2 h to determine the low-density CPP (LCPP) level. The high-density CPP (HCPP) level was calculated by subtracting the LCPP level from the total CPP level.

**Measurement of CPP by the fetuin-A method**

The serum fetuin-A level (= F1) was measured using a human fetuin-A ELISA kit. Next, the serum was centrifuged at 16,000–24,000 g for 2 h to precipitate CPP. The fetuin-A level in the supernatant (= F2) was measured using the ELISA kit. Lastly, the fetuin-A reduction rate defined as (F1–F2)/F1 was calculated and used as a surrogate for the serum CPP level [8, 9].

**Statistical analysis**

The data are expressed as mean ± SD or median (interquartile range) according to distribution of the data. All statistical analyses were performed using StatMate IV. p value < 0.05 was considered statistically significant. Comparisons between two groups were performed using Wilcoxon signed-rank test or Student’s t test. Spearman rank correlation was performed to determine correlations with continuous variables.

**Result**

**Clinical and laboratory characteristics**

Clinical and biochemical characteristics of the 24 HD patients are summarized in Table 1.

Eleven HD patients suffered from DM. Considering the concentration of Kt/V, Ca, P, Ca×P, and iPTH, patients in this study had been appropriately treated. FGF23 level was higher and fetuin-A level was lower than the normal range, which was consistent with a previous report [14, 15]. Klotho was maintained within the normal range (Table 1). Table 2 shows the effects of switching CC to LC on laboratory data. All the data were not significantly changed except that iPTH was elevated after the switch.

**The effect of the switch from CC to LC on CPP**

TCPP and LCPP levels were significantly decreased after switching CC to LC (TCPP; P < 0.05, LCPP; p < 0.05). We were unable to determine HCPP levels because they were below the lower detection limit. The fetuin-A method also failed to measure serum CPP levels (Fig. 2).

**Correlations**

The changes in Ca × P and P before and after the switch of phosphate binders were positively correlated with those in TCPP. However, the changes in Ca did not correlate with those in TCPP. Interestingly, the reduction of TCPP

| Table 1 Clinical and laboratory characteristics of patients |
|----------------------------------------------------------|
| Age (years) | 68 ± 12 |
| Sex male (%) | 12 (50) |
| BMI (kg/m²) | 21.2 ± 2.3 |
| SBP (mmHg) | 144 ± 23 |
| DBP (mmHg) | 76 ± 13 |
| Period of hemodialysis (years) | 5 (2–10) |
| Kt/v | 1.74 ± 0.34 |
| ACI (%) | 46.8 ± 27.1 |
| GNRI | 98.0 ± 5.8 |
| Serum albumin (g/dl) | 3.9 ± 0.2 |
| LDL cholesterol (mmol/l) | 79.1 (62.6–106.3) |
| Serum Ca (mg/dl) | 9.0 (8.4–9.7) |
| Serum P (mg/dl) | 5.4 (4.4–6.3) |
| Ca×P₀₄ product | 48.8 (39.3–54.9) |
| iPTH (pg/ml) | 88.0 (41.3–151.0) |
| FGF23 (Log) (pg/ml) | 1.3 (0.6–2.8) |
| α-Klotho (pg/ml) | 428.2 (380.2–659.2) |
| Fetuin-A (µg/ml) | 230.8 (193.9–240.8) |
| hs-CRP (mg/l) | 0.3 (0.2–0.9) |

Data are expressed as mean ± SD or number (percentage) or median (interquartile range)
showed significant negative correlation with the TCPP level at the time of the drug switch (Fig. 3). In the present study, the changes in LDL cholesterol were positively correlated with those in TCPP, but the changes in hs-CRP and ACI were not correlated with those in TCPP (Fig. 4).

Discussion

To our knowledge, this study is the first report that assessed the efficacy of LC on CPP in HD patients in a short period.
When phosphate concentrations are raised by 1–2 mM in regular cell culture medium, insoluble calcium–phosphate crystals appear [16]. Calcium–phosphate crystals caused cellular responses such as production of reactive oxygen species without raising the phosphate level in the medium. These responses did not occur in high phosphate medium when calcium–phosphate crystals were removed or their formation was inhibited [5, 6]. Thus, calcium–phosphate crystals, but not phosphate, may be responsible for the cellular responses to high phosphate medium. The smallest calcium–phosphate

---

**Fig. 3** The changes in Ca×P and P before and after the switch of phosphate binders were positively correlated with those in TCPP. The changes in Ca did not correlate with those in TCPP. The reduction of TCPP showed significant negative correlation with those in TCPP.

**Fig. 4** The changes in LDL cholesterol before and after the switch of phosphate binders were positively correlated with those in TCPP. The changes in hs-CRP and ACI were not correlated with those in TCPP.
precipitates called Posner’s clusters aggregate and transform into amorphous calcium–phosphate, and eventually grow into hydroxyapatite [17]. However, in the presence of mineral-binding proteins such as fetuin-A, Posner’s clusters are adsorbed by fetuin-A and are prevented from growing large calcium–phosphate precipitates [3]. The aggregation of calcium–phosphate and fetuin-A forms nanoparticles, which are called CPP, and dispersed as colloids [4].

Recent studies have suggested that CPP have a pathogenic role that causes VC [5, 6]. Smith et al. indicated that CPP stimulated pro-inflammatory and pro-apoptotic cascades in macrophages [7]. Sage et al. reported that CPP caused transition of vascular smooth muscle cells to osteoblast-like cells [16]. Furthermore, serum CPP levels were increased with CKD progression and correlated with vascular stiffness and calcification [8, 9]. These observations imply that it may be of therapeutic importance to control CPP levels.

Dietary restriction of phosphate intake and removal of phosphate by dialysis are not always sufficient to maintain serum phosphate within the normal range. Therefore, many dialysis patients are prescribed phosphate binders. Nonetheless, many dialysis patients suffer from VC even when serum phosphate levels are controlled within the normal range.

CC are widely applied for hyperphosphatemic patients, but are associated with progressive VC [18]. The associations between VC and exogenous calcium intake, Ca × P and serum calcium levels were reported [19]. Non-calcium-based phosphate binders such as LC [20, 21] have been associated with less VC than CC [10], which may be explained by the fact that LC lowers serum CPP levels more efficiently than CC.

Recently, some new measurement methods have been discovered for CPP. Hamano et al. measured CPP levels indirectly using fetuin-A [8]. The mechanism behind the link between ΔLDL and ΔTCP is to be determined. Because scavenger receptors are involved in clearance of both CPP and LDL from the blood, decrease in TCP may have facilitated clearance of LDL [22].

CPP maturation time (T50) in serum is a novel measure of individual blood calcification propensity [23]. A long delay of T50 indicates a high residual capacity of the patient’s serum to prevent the formation of secondary CPPs and is therefore indicative of an intact endogenous defense against calcification. High-flux hemodialysis and hemodiafiltration lead to improved T50 in minutes. In this study, high-flux hemodialysis and hemodiafiltration were not done.

In this study, CPP was significantly decreased after switching drugs regardless of Ca × P and phosphate levels. LC is not absorbed from the intestinal tract but CC is absorbed with phosphate. The calcium load may increase the risk for formation of CPP. Namely, calcium in CC absorbed from the intestine may contribute to CPP in the blood. The gel-filtration method can distinguish between LCPP and HCPP. HCPP are equivalent to the CPP measured by the fetuin-A method, which are thought independently correlated with serum phosphate, CRP, oxidized LDL and BMP-2/7 [9]. However, we were unable to measure HCPP because the serum HCPP levels were too low to measure using the gel-filtration method or the fetuin-A method. This may be due to the fact that dialysis patients enrolled in this study were well controlled by hemodialysis and phosphate binders. Serum CPP levels were not correlated with ACI and hs-CRP. In the present study, serum LCPP levels, which were equivalent to TCP, were correlated with P, Ca × P, LDL cholesterol. It may be important to control serum LCPP before they aggregate and grow into HCPP that can cause VC and inflammatory responses.

The limitations of this study include small sample size and a short observation period. Further studies in patients with high HCPP level are needed.

Acknowledgements The funding was received from AMED-CREST with Grant No. JP19gm0610012.

Compliance with ethical standards

Conflicts of interest The authors have declared that no conflict of interest exists.

Ethical approval The study protocol was approved by the review committee of Yamaguchi University (Approval Number H23-156) and was conducted in accordance with the Declaration of Helsinki.

Informed consent General informed consent was obtained according to the local ethical committee guidelines.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69:1945–53.
2. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, et al. Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study. Kidney Int. 2005;67:1179–87.
3. Heiss A, Pipich V, Jahnhen-Dechent W, Schwahn D. Fetuin-A is a mineral carrier protein: Small angle neutron scattering provides new insight on fetuin-A controlled calcification inhibition. Biophys J [Internet]. Biophysical Society; 2010;99:3986–95. https://dx.doi.org/10.1016/j.bpj.2010.10.030
4. Kuro-O M. A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease. Kidney Int Suppl. Elsevier Masson SAS. 2013;3:420–6.
5. Villa-Bellosta R, Sorribas V. Phosphonoformic acid prevents vascular smooth muscle cell calcification by inhibiting calcium–phosphate deposition. Arterioscler Thromb Vasc Biol. 2009;29:761–6.
6. Ewence AE, Bootman M, Roderick HL, Skepper JN, McCarthy G, Epple M, et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells. Circ Res. 2008;103:28–34.
7. Smith ER, Hanssen E, McMahon LP, Holt SG. Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage. PLoS One 2013;8:e60904.
8. Hamano T, Matsui I, Mikami S, Tomida K, Fujii N, Imai E, et al. Fetuin-mineral complex reflects extrasosseous calcification stress in CKD. J Am Soc Nephrol. 2010;21:1998–2007.
9. Smith ER, Ford ML, Tomlinson LA, Rajkumar C, McMahon LP, Holt SG. Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol Dial Transplant. 2012;27:1957–66.
10. Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrol. 2011;16:290–8.
11. Daugirdas JT, Finn WF, Emmett M, Chertow GM. The phosphate binder equivalent dose. Semin Dial. 2011;24:41–9.
12. Ohya M, Otani H, Kimura K, Saika Y, Fujii R, Yukawa S, et al. Vascular calcification estimated by aortic calcification area index is a significant predictive parameter of cardiovascular mortality in hemodialysis patients. Clin Exp Nephrol. 2011;15:877–83.
13. Miura Y, Iwazu Y, Shizaki K, Akimoto T, Kotani K, Kurabayashi M, et al. Identification and quantification of plasma calciprotein particles with distinct physical properties in patients with chronic kidney disease. Sci Rep. 2018;8:1–16.
14. Fukagawa M, Kazama JJ. With or without the kidney: the role of FGF23 in CKD. Nephrol Dial Transplant. 2005;20:1295–8.
15. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003;361:827–33.
16. Sage AP, Lu J, Tintut Y, Demer LL. Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int [Internet]. Elsevier Masson SAS; 2011;79:414–22. https://dx.doi.org/10.1038/ki.2010.390
17. Kanazaki N, Treboux G, Onuma K, Tsutsumi S, Ito A. Calcium phosphate clusters. Biomaterials. 2001;22:2921–9.
18. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2004;19:1489–96.
19. Block GA. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients. Clin Nephrol 2000;54:318–24.
20. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis [Internet]. National Kidney Foundation, Inc.; 2003;42:96–107. https://dx.doi.org/10.1016/S0272-6386(03)00554-7
21. Shigematsu T, Group the LC. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol. 2008;70:404–10.
22. Pasch A, Pasch A, Dersande F, Konings C, Bachtler M, Dionisi M, et al. High-flux hemodialysis and high-volume hemodiafiltration improve serum calcification propensity. PLoS ONE. 2016;11:1–13.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.